{"nctId":"NCT00620555","briefTitle":"A Phase III Open-Label Extension Study Of Gabapentin As Adjunctive Therapy In Japanese Pediatric Patients With Partial Seizures","startDateStruct":{"date":"2008-05"},"conditions":["Epilepsies, Partial"],"count":65,"armGroups":[{"label":"gabapentin","type":"EXPERIMENTAL","interventionNames":["Drug: gabapentin"]}],"interventions":[{"name":"gabapentin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Completion of study A9451162 (NCT00603473)\n\nExclusion Criteria:\n\n* Seizures related to drugs or acute medical illness\n* History of any serious medical or psychiatric disorder","healthyVolunteers":false,"sex":"ALL","minimumAge":"3 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Treatment-Emergent Adverse Events (All Causalities and Treatment-Related)","description":"Any untoward medical occurrence in a participant who received study drug was considered an adverse event (AE), without regard to possibility of causal relationship. Treatment-emergent adverse events: those which occurred or worsened after baseline. Severe AEs: those which interferes significantly with participant's usual function. An AE resulting in any of the following outcomes, was considered to be a serious adverse event: death; life-threatening; initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Response Ratio","description":"The Response Ratio calculated by the following equation : Response Ratio = (T minus B) divided by (T plus B), where T is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 52-week treatment period, and B is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 6-week baseline period of the previous study A9451162 (NCT00603473).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.263","spread":"0.3141"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.256","spread":"0.3513"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.300","spread":"0.3671"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.280","spread":"0.3753"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.327","spread":"0.3712"}]}]}]},{"type":"SECONDARY","title":"Responder Rate","description":"Responder Rate was defined as the percentage of subjects with a 50 percent or greater reduction in the seizure frequency per 28 days for the 52-week treatment period in comparison with the frequency per 28 days for the 6-week baseline period of the previous study A9451162 (NCT00603473).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change in Seizure Frequency","description":"Percent change in seizure frequency (PCH) was calculated as follows: PCH = 100\\*(T minus B) divided by B, where T is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 52-week treatment period, and B is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 6-week baseline period of the previous study A9451162 (NCT00603473).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-34.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-33.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-42.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-41.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-49.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":65},"commonTop":["Nasopharyngitis","Somnolence","Influenza","Pyrexia","Diarrhoea"]}}}